Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAGOTTO: Renoprotective effect of canagliflozin in diabetic kidney disease
jRCTs041200069Recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of canagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Dec 2020; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs041200069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200069.